2 news items
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
CMMB
6 Jun 24
, they are subject to various risks and uncertainties and actual results, performance or achievements of Chemomab could differ materially from those
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
CMMB
25 Mar 24
of Chemomab could differ materially from those described in or implied by the statements in this presentation, including those found under the caption
- Prev
- 1
- Next